Oncology Today with Dr Neil Love

Featuring an interview with Dr Rana R McKay, including the following topics:
Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
Takeaways from the Phase III EMBARK study (19:36)
Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:
Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)
Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)
Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)
Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)
Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)

NCPD information and select publications

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics:
Introduction (0:00)
Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)
Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics:
Introduction (0:00)
Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)
Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)
Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)
Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)

CME information and select publications

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:
Introduction (0:00)
Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)
Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)

CME information and select publications